Search clinical trials for: Temsirolimus and pemetrexed for recurrent or refractory NSCLC

Total 491399 results

Wuhan Union Hospital, China

Recruiting

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC (NEOSUN)

Non Small Cell Lung Cancer

China
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01)

Metastatic Lung Cancer

France
Memorial Sloan Kettering Cancer Center
Chugai Pharma USA

Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Primary Extra-cranial Solid Tumor | Recurrent or Refractory Glypican 3 (GPC3)

United States
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (CHIPRO)

Ovarian Cancer | Relapsed or Refractory | Chiauranib | Paclitaxel

China
Shanghai OriginCell Therapeutics Co., Ltd.

Not yet recruiting

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Lakshmi Nayak, MD
Kazia Therapeutics Limited

Recruiting

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Primary Central Nervous System Lymphoma | Non-Hodgkin Lymphoma of Extranodal Site

United States
Jakob Stenman
Novartis; Advanced Accelerator Applications

Recruiting

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

Neuroblastoma | Neuroblastoma Recurrent

Sweden, Denmark, Lithuania, Norway, Netherlands
Mayo Clinic

Recruiting

Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Adenoid Cystic Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
Emory University
National Cancer Institute (NCI); Novartis; Secura Bio, Inc.

Recruiting

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
University of Washington
Genzyme, a Sanofi Company

Recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI); Incuron LLC

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study

Refractory or Recurrent Neuroblastoma in Children
National Cancer Institute (NCI)

Recruiting

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma

United States
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Solid Tumor | Recurrent Glioma

China
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
M.D. Anderson Cancer Center

Recruiting

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Taizhou Hanzhong biomedical co. LTD

Recruiting

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Nonsquamous Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Recruiting

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (CREATIVE)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma

United States
McGill University Health Centre/Research Institute...

Recruiting

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell

Canada
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States, Belgium
Joseph Tuscano
National Cancer Institute (NCI); Seagen Inc.

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Recurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 Glioma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Recruiting

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Desmoplastic Small Round Cell Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Ewing Sarcoma/Peripheral... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Malignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
BioNTech Cell & Gene Therapies GmbH

Recruiting

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Solid Tumor

Australia, Germany, Netherlands, Sweden
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (ACROSS1)

Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
Beijing Immunochina Medical Science & Technology...
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NHL

China

Search clinical trials for: Temsirolimus and pemetrexed for recurrent or refractory NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations